Psychedelic Therapy Hits Another Milestone, But Caution Urged
Psychiatric News July 22, 2021 DOI: 10.1176/appi.pn.2021.7.14 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | MDMA-assisted therapy |
| Topics | Psychedelic-assisted therapy |
| Keywords | Milestone Center of excellence Psychotherapist Law |
| Key points | Reports that positive phase 3 trial findings have brought MDMA-assisted therapy closer to FDA approval, while experts remain unclear how long its effects last. Notes that when Charles Raison joined the Usona Institute's scientific board in 2015, Usona was one of few US nonprofits studying psychedelics, and that the psychedelic medicine industry is now believed to be a $100 billion investment opportunity. |
Abstract
Positive findings from a phase 3 trial may have brought MDMA-assisted therapy closer to FDA approval, but experts remain unclear about how long the effects of the therapy might last. When Charles Raison, M. D. , a professor of psychiatry and the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families at the University of Wisconsin-Madison joined the scientific board at the nonprofit Usona Institute in 2015, he was stepping into uncharted territory. At the time, Usona was one of only a few nonprofits in the United States studying psychedelics. Today, the psychedelic medicine industry is believed to be an investment opportunity worth $100 billion.